Provenge is currently not available.
Our suppliers are constantly updating their product inventory and availability status. If you would like us to notify you when Provenge becomes available, please fill out the form below.
*We value your privacy! We will never give, lease, sell or otherwise disclose your personal information. Period!
Browse Alphabetically:
A · B · C · D · E · F · G · H · I · J · K · L · M · N
O · P · Q · R · S · T · U · V · W · X · Y · Z · #
Information about ExpressMedsCanada.com
List of countries where we can ship Provenge:
Latest news releases on Provenge:
NEW YORK - Shares of Dendreon Corp. sank Wednesday after a Jefferies & Co. analyst said the company's prostate cancer therapy Provenge will be eclipsed by two newer competitors. THE SPARK: Analyst Biren Amin started covering Dendreon shares with an ...
With each era of discovery it seems there is always a leader with the innovative foresight and fortitude to lead a revolution and conquer a foe. The tools used to defeat the enemy are considered to be marvels and are viewed as such by outsiders willing to ...
NEW YORK (AP) -- Shares of Dendreon Corp. sank Wednesday after a Jefferies & Co. analyst said the company's prostate cancer therapy Provenge will be eclipsed by two newer competitors. THE SPARK: Analyst Biren Amin started covering Dendreon ...
It seems that not a day goes by without a fierce debate over Provenge, its efficacy, and its future place in the prostate cancer market. Over the past year, Dendreon has suffered mightily, with the stock falling almost 82% as Provenge forecasts were cut ...
SEATTLE, May 16, 2012 (BUSINESS WIRE) -- May 16, 2012--Dendreon Corporation (NASDAQ:DNDN) today announced the following PROVENGE(R) (sipuleucel-T) data will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting taking ...
Dendreon Corp. (DNDN) said the U.S. Securities and Exchange Commission has begun a formal investigation, which may be related to shareholder lawsuits alleging the company misled investors about prostate-cancer drug Provenge. Dendreon said in its ...
May 21, 2012–Dendreon Corporation (NASDAQ: DNDN) today announced the following PROVENGE® (sipuleucel-T) data will be presented at the American Urological Association (AUA) Annual Meeting taking place May 19 – 23, 2012 in Atlanta ...
Dendreon makes Provenge, a prostate cancer treatment, but is facing competition from Johnson & Johnson’s (JNJ) drug Zytiga, as well as drug candidate MDV 3100 made by Medivation and Astellas Pharma. Against those two drugs, “we believe ...
From the moment Dendreon started in business 20 years ago, most scientists have said that if its immune-booster for prostate cancer was going to work, it would probably work best at an early stage of disease, before tumors had gotten too ...
The biotech's stock, down almost 80% since last year, plunged Tuesday after the maker of Provenge announced another quarterly loss. Dendreon has suffered a major relapse. Shares of Dendreon (ticker: DNDN), which is focused on cancer treatments ...